logo
Plus   Neg
Share
Email

Amgen Reports Positive Results For Otezla In Phase 3 Trial

Amgen (AMGN) Wednesday announced positive results from the ADVANCE trial, a Phase 3 study to assess the efficacy of Otezla or Apremilast in adults with mild-to-moderate plaque psoriasis.

The multicenter, randomized, placebo-controlled, double-blind study showed that oral Otezla 30 mg twice daily achieved a statistically significant improvement, compared with placebo.

The trial achieved 75 percent improvement from baseline at week-16, confirming the secondary endpoints.

Currently, Otezla is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis.

Psoriasis is a serious, chronic inflammatory disease that causes raised, red, scaly patches to appear on the skin, typically affecting the outside of the elbows, knees or scalp.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Supermarket chain Wegmans Food Markets, Inc. is recalling select Valencia oranges, lemons, and various other products containing fresh lemon citing potential contamination with Listeria monocytogenes, the U.S. Food and Drug Administration announced. The recall was initiated after Wegmans' lemons and oranges supplier Freshouse Produce LLC, issued a recall of its supplies. A California court ruled that Uber and Lyft must classify their drivers as employees in a preliminary injunction issued on Monday. However, the court has stayed the injunction for 10 days to allow the ride-hailing service providers to appeal the decision. Hyundai Motor has launched a new IONIQ brand dedicated to battery electric vehicles, as the automaker is accelerating its efforts to gain a share in the fast-growing global EV market. Under the IONIQ brand, Hyundai plans to introduce three new dedicated electric vehicle models over the next four years. Hyundai is South Korea's largest automaker.
Follow RTT